إپراتروپيوم بروميد/سالبوتامول
|
إپراتروپيوم بروميد/سالبوتامول Ipratropium bromide/salbutamol
| |
| مجموع | |
| الاسم النظامي (أيوپاك) | |
| Ipratropium bromide | Muscarinic antagonist |
| Salbutamol | Short-acting β2-adrenergic agonist |
| المعينات Identifiers | |
| رقم CAS | ? |
| كود ATC | R03 |
| PubChem | ? |
| بيانات كيميائية | |
| الصيغة | ? |
| كتلة جزيئية | ? |
| بيانات الحركية الدوائية Pharmacokinetic | |
| التوافر الحيوي | ? |
| الأيض | ? |
| عمر النصف | ? |
| اخراج | ? |
| اعتبارات علاجية | |
| فئة السلامة أثناء الحمل |
C |
| الوضع القانوني |
Pharmacist Only (S3)(استراليا) POM(المملكة المتحدة) (الولايات المتحدة) |
| المسارات | Inhalation |
إپراتروپيوم/سالبوتامول، يُباع تحت الاسم التجاري كومبيڤنت Combivent، هوcombination medication used to treat chronic obstructive pulmonary disease (COPD). It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a -adrenergic agonist). It is taken by inhalation.
Common side effects include sore throat, muscle cramps, and nausea. Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections. Safety in pregnancy is unclear. Each medication typically decreases bronchospasm and does so via different mechanisms.
The combination was approved for medical use in the United States in 1996. It is available as a generic medication. Sixty doses in the United Kingdom costs the NHS about 18 £ as of 2019. In the United States the wholesale cost of this amount is about US$9.50. In 2016 it was the 166th most prescribed medication in the United States with more than ثلاثة million prescriptions.
المجتمع والثقافة
Since Combivent contains a chlorofluorocarbon based propellant, it is being phased out in European Union countries. Chloroflourocarbons (CFC) are attributed to depletion of the ozone layer.
المصادر
- ^ "Albuterol / ipratropium Use During Pregnancy". Drugs.com (in الإنجليزية). Retrieved 19 April 2019.
- ^ "DailyMed - ipratropium bromide and albuterol sulfate inhalant". dailymed.nlm.nih.gov. Retrieved 18 April 2019.
- ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 247. ISBN .
- ^ "Ipratropium and Albuterol - FDA prescribing information, side effects and uses". Drugs.com (in الإنجليزية). Retrieved 18 April 2019.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in الإنجليزية). Retrieved 3 March 2019.
- ^ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
وصلات خارجية
- DailyMed
- Consumer Medication Information from PubMed
- National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.
نطقب:Muscarinic acetylcholine receptor modulators
